Last reviewed · How we verify
epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile
epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile is a anthracycline antibiotic Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Breast cancer, Lung cancer, Lymphoma.
Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells.
Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Used for Breast cancer, Lung cancer, Lymphoma.
At a glance
| Generic name | epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile |
|---|---|
| Sponsor | Sanofi |
| Drug class | anthracycline antibiotic |
| Target | topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epidoxorubicine works by intercalating DNA strands, which prevents the enzyme topoisomerase II from unwinding DNA during replication, ultimately leading to cell death. This mechanism is specific to rapidly dividing cancer cells, making it an effective treatment for various types of cancer.
Approved indications
- Breast cancer
- Lung cancer
- Lymphoma
Common side effects
- Myelosuppression
- Cardiotoxicity
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile CI brief — competitive landscape report
- epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile
What is epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile?
How does epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile work?
What is epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile used for?
Who makes epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile?
What drug class is epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile in?
What development phase is epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile in?
What are the side effects of epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile?
What does epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile target?
Related
- Drug class: All anthracycline antibiotic drugs
- Target: All drugs targeting topoisomerase II
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer
- Indication: Drugs for Lung cancer
- Indication: Drugs for Lymphoma
- Compare: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile vs similar drugs
- Pricing: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile cost, discount & access